SWITCH: Apixaban vs Vitamin K in HM3

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 460 participants.

Also called NCT07471139

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 460 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07471139
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07471139. Randomized; no masking; primary purpose treatment. Start 2026-10-15 (actual); primary completion 2029-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SWITCH: Apixaban vs Vitamin K in HM3
Condition
LVAD (Left Ventricular Assist Device) Thrombosis
Condition
Heart Failure
Condition
Bleeding
Condition
Thrombosis; Artery
Condition
Stroke
Condition
Heart Transplant
Intervention (Drug)
Warfarin
Intervention (Drug)
Apixaban
Lead sponsor
Columbia University (class: other)

Record details

Record id
cardio:ct-nct07471139
Content hash
61b29ef718d33041250e5949c14b2f6920823643b6b7ca2b054985597113bf24